Prediction and Evaluation of Anlotinib Treatment Response Using Contrast Enhanced Ultrasound PPGL Patients

Inclusion Criteria: * 18 years of age or older. * Provide written informed consent. * Willing to return to enrolling institution for follow-up. * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2. * Life expectancy \> 3 months. * Patients diagnosis with pheochromocytoma or paraganglioma will received anlotinib treatment. * Laboratory requirements: * Absolute granulocyte count (AGC) greater than 1.5 x 109/L; * Platelet count greater than 80 x 109/L; * Hemoglobin greater than 90g/L; * Serum bilirubin less than 1.5 x upper limit of normal (ULN); * Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 2.5 x ULN; * Serum creatinine less than 1.5 x ULN or creatinine clearance (CCr)≥60ml/min; * Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ lower limit of normal value (50%). Exclusion Criteria: * Patients who are allergic to ultrasound contrast agents. * Any of the following:Pregnant women,Nursing women,Men or women of childbearing potential who are unwilling to employ adequate contraception. * Patients who have previously used other anti-vascular targeted drugs, such as sunitinib, bevacizumab, endurance, etc. * Chemotherapy/systemic therapy, radiotherapy, immunotherapy or surgery within 4 weeks prior to kinase inhibitor therapy. * Patients with another primary malignancy within 5 years prior to starting study drug. Those who have multiple factors that affect oral medications (such as …